1. Home
  2. TGTX vs ST Comparison

TGTX vs ST Comparison

Compare TGTX & ST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TGTX
  • ST
  • Stock Information
  • Founded
  • TGTX 1993
  • ST 1916
  • Country
  • TGTX United States
  • ST United States
  • Employees
  • TGTX N/A
  • ST N/A
  • Industry
  • TGTX Biotechnology: Pharmaceutical Preparations
  • ST Industrial Machinery/Components
  • Sector
  • TGTX Health Care
  • ST Industrials
  • Exchange
  • TGTX Nasdaq
  • ST Nasdaq
  • Market Cap
  • TGTX 4.2B
  • ST 4.7B
  • IPO Year
  • TGTX 1995
  • ST 2010
  • Fundamental
  • Price
  • TGTX $32.18
  • ST $31.42
  • Analyst Decision
  • TGTX Strong Buy
  • ST Buy
  • Analyst Count
  • TGTX 4
  • ST 13
  • Target Price
  • TGTX $42.50
  • ST $33.38
  • AVG Volume (30 Days)
  • TGTX 2.0M
  • ST 1.2M
  • Earning Date
  • TGTX 11-03-2025
  • ST 11-03-2025
  • Dividend Yield
  • TGTX N/A
  • ST 1.49%
  • EPS Growth
  • TGTX N/A
  • ST 1246.54
  • EPS
  • TGTX 0.36
  • ST 0.74
  • Revenue
  • TGTX $454,069,000.00
  • ST $3,745,159,000.00
  • Revenue This Year
  • TGTX $82.58
  • ST N/A
  • Revenue Next Year
  • TGTX $44.99
  • ST $3.53
  • P/E Ratio
  • TGTX $89.78
  • ST $43.59
  • Revenue Growth
  • TGTX 30.96
  • ST N/A
  • 52 Week Low
  • TGTX $21.16
  • ST $17.32
  • 52 Week High
  • TGTX $46.48
  • ST $37.40
  • Technical
  • Relative Strength Index (RSI)
  • TGTX 57.80
  • ST 47.03
  • Support Level
  • TGTX $31.34
  • ST $31.26
  • Resistance Level
  • TGTX $32.57
  • ST $32.31
  • Average True Range (ATR)
  • TGTX 1.13
  • ST 0.79
  • MACD
  • TGTX 0.54
  • ST -0.16
  • Stochastic Oscillator
  • TGTX 76.10
  • ST 9.11

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

About ST Sensata Technologies Holding plc

Sensata Technologies is a global supplier of sensors for transportation and industrial applications. Sensata sells a bevy of pressure, temperature, force, and position sensors into the automotive, heavy vehicle, industrial, heating, ventilation, and cooling, and aerospace markets. The majority of the firm's revenue comes from the automotive market, where it focuses on bumper-in applications.

Share on Social Networks: